Javascript must be enabled to continue!
Endoscopic features of deficient mismatch repair/microsatellite instability‐high and BRAF‐mutated colorectal cancer
View through CrossRef
AbstractObjectiveRecent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC). BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have demonstrated significant prognostic improvement following recent immune checkpoint inhibitor therapy. Therefore, the diagnosis of these subtypes is important. This study aimed to identify the endoscopic features of dMMR/MSI‐high and BRAF‐mutated CRCs.MethodsA retrospective analysis was conducted on 292 CRC cases. Clinicopathological findings, focusing on dMMR/MSI‐H and BRAF‐mutated subtypes, were determined. Endoscopic images were analyzed for the presence of yellow slough. Surface material characteristics were assessed through a histopathological evaluation.ResultsOf the 256 cases analyzed, 27 were dMMR/MSI‐H CRC, including 12 BRAF‐mutant cases. Yellow slough was observed in 83.3% of dMMR/MSI‐H and BRAF‐mutated CRCs, compared with 13.3% dMMR/MSI‐H and BRAF wild‐type CRCs and 1.3% pMMR/MSS and BRAF wild‐type CRCs. Histological examination showed a correlation of yellow slough with coagulative necrosis and thicker surface layers in dMMR/MSI‐high and BRAF‐mutated CRCs.ConclusionYellow slough on endoscopy may help identify dMMR/MSI‐H‐ and BRAF‐mutated CRC and allow the initiation of appropriate molecular testing and immunotherapy
Title: Endoscopic features of deficient mismatch repair/microsatellite instability‐high and BRAF‐mutated colorectal cancer
Description:
AbstractObjectiveRecent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC).
BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have demonstrated significant prognostic improvement following recent immune checkpoint inhibitor therapy.
Therefore, the diagnosis of these subtypes is important.
This study aimed to identify the endoscopic features of dMMR/MSI‐high and BRAF‐mutated CRCs.
MethodsA retrospective analysis was conducted on 292 CRC cases.
Clinicopathological findings, focusing on dMMR/MSI‐H and BRAF‐mutated subtypes, were determined.
Endoscopic images were analyzed for the presence of yellow slough.
Surface material characteristics were assessed through a histopathological evaluation.
ResultsOf the 256 cases analyzed, 27 were dMMR/MSI‐H CRC, including 12 BRAF‐mutant cases.
Yellow slough was observed in 83.
3% of dMMR/MSI‐H and BRAF‐mutated CRCs, compared with 13.
3% dMMR/MSI‐H and BRAF wild‐type CRCs and 1.
3% pMMR/MSS and BRAF wild‐type CRCs.
Histological examination showed a correlation of yellow slough with coagulative necrosis and thicker surface layers in dMMR/MSI‐high and BRAF‐mutated CRCs.
ConclusionYellow slough on endoscopy may help identify dMMR/MSI‐H‐ and BRAF‐mutated CRC and allow the initiation of appropriate molecular testing and immunotherapy.
Related Results
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
70
Background:
BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less ...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract
BRAF protein kinases act downstream of RAS-GTP and upstream of MEK>ERK MAP Kinase signaling. Notably, mutational activation of BRAF is a driver of ap...
Detection of Pan Braf in Thyroid Tumors in Iraqi Patients
Detection of Pan Braf in Thyroid Tumors in Iraqi Patients
The B-type Raf kinase (BRAF) is a member of RAS\RAF\MEK\ERK pathway and this pathway can lead to increased cellular growth, invasion and metastasis. The mutated BRAF protein activa...
A pan-cancer statistical study of microsatellite instability and Lynch syndrome–associated mismatch repair genes germline mutations.
A pan-cancer statistical study of microsatellite instability and Lynch syndrome–associated mismatch repair genes germline mutations.
10593 Background: Lynch Syndrome (LS), known as hereditary nonpolyposis colorectal cancer (HNPCC1), is caused by germline mutations in the mismatch repair (MMR) genes ( MLH1, MSH2...
Abstract 1096: microRNA-193a-3p acts as a tumor suppressor in BRAF-mutated colorectal cancer
Abstract 1096: microRNA-193a-3p acts as a tumor suppressor in BRAF-mutated colorectal cancer
Abstract
The aim of this study was to identify microRNAs (miRNAs) specifically dysregulated in BRAF-mutant colorectal cancer, a malignant subtype of colorectal cance...
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to ...
BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience
BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience
BackgroundPediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAFV600E alteration may have worse outcomes, particularly when tr...

